EndLeukemia Assay (NGS)

The EndLeukemia mutation screening assay is a next-generation sequencing (NGS) based test designed to screen for somatic mutations in exonic regions of 81 genes with therapeutic and/or prognostic importance in hematological malignancies. Detailed profiling of the mutations existing in the tumor is warranted to understand the genetic basis of cancer and improve overall patient diagnosis and treatment.

Genomic DNA from peripheral blood or bone marrow is fragmented using restriction enzymes, followed by oligonucleotide probe hybridization, creating circularized DNA molecules containing the target regions. The DNA molecules are ligated, captured, and amplified by PCR, with sequencing performed on Illumina’s NextSeq instrument.

Clinical specimens were reviewed for the markers listed:

Seven days for routine and STAT 

10 ml peripheral blood (PB) in purple-top (lavender top) tube (EDTA Vacutainer), sent on wet ice

or

2–5 ml of bone marrow aspirate (BM), sent on wet ice

81455

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.